Optimal immunosuppressive regimen for hepatitis B-positive kidney transplant recipients.
Hsieh
H
H
Chang Gung Medical College, Taiwan.
Chen
C H
CH
Huang
H F
HF
Tseng
Y J
YJ
D000206:Actuarial Analysis; D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006085:Graft Survival; D006509:Hepatitis B / Q000150:complications* / Q000401:mortality; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D015996:Survival Rate
D006514:Hepatitis B Surface Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011241:Prednisone